Novartis India Approves Termination Of Distribution Agreement With Dr. Reddy’s Laboratories; Termination Agreement With Dr. Reddy’s Effective September 30, 2026; To Re-Buy Exclusivity And Market Access For Products After DRL Agreement Termination

Novartis Enters Strategic Collaboration with Dren Bio for Oncology Research

Novartis Pharma AG, a subsidiary of Novartis AG, has entered into a strategic collaboration with Dren Bio to discover and develop bispecific antibodies for cancer treatment.

Should You Buy Royalty Pharma Stock Before Nov. 4?

Royalty Pharma shares have rallied toward 52-week highs ahead of Q3 2026 earnings on Nov. 4, but investors should focus on long-term prospects rather than short-term earnings catalysts. Analysts expect 8.7% sales growth and flat earnings, with potential upside from positive pipeline updates on cancer treatments and other drug candidates, though negative news on pelacarsen could weigh on the stock.

Global Dermatological Therapeutics Market to Reach USD 97 Billion by 2034 | DelveInsight

The global dermatological therapeutics market is projected to grow from USD 43 billion in 2025 to USD 97 billion by 2034, with a CAGR of approximately 10%. Growth is driven by rising prevalence of chronic skin disorders, adoption of biologics and JAK inhibitors, increased healthcare spending, and growing awareness of skin health. North America leads the market with 46% share, while Asia-Pacific is expected to register the fastest growth.

RBC Raises Price Target on Novartis to CHF130

RBC Capital Markets has increased its price target for Novartis AG from CHF120 to CHF130 while maintaining a Sector Perform rating.

Jefferies Upgrades Dr. Reddy's Laboratories to Hold from Sell

Investment firm Jefferies has upgraded its rating for Dr. Reddy's Laboratories from 'Sell' to 'Hold' and set a price target of $13.90.

Dr Reddy's Laboratories Q2 EPS $0.12 Misses $0.16 Estimate, Sales $905.000M Miss $980.650M Estimate